Through the institute, UVA will build on its expertise in biotechnology. UVA’s ability to manufacture gene and cell therapy solutions at a large scale to support clinical trials and other essential steps in the development process toward FDA approval will grow with the institute.

The Manning Institute is anticipated to attract pharmaceutical and biotech companies to what is expected to become a major hub for research and manufacturing centered around UVA’s new state-of-the-art biotech facility.